{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:59:53Z","timestamp":1790409593157,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.05.224","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:12:37Z","timestamp":1779808357000},"page":"25-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Lifestyle and pharmacologic interventions for adults with hypertriglyceridemia: Critical to reduce risk of ASCVD and pancreatitis but often underutilized"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5089-9494","authenticated-orcid":false,"given":"Carol F.","family":"Kirkpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-850X","authenticated-orcid":false,"given":"Vera A.","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jacl.2026.05.224_bib1","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.05.224_bib2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","article-title":"Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association","volume":"19","author":"Javed","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.05.224_bib3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jacl.2025.03.012","article-title":"Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology","volume":"19","author":"Saadatagah","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2026.05.224_bib4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacl.2022.07.011","article-title":"Nutrition interventions for youth with dyslipidemia: a National Lipid Association Clinical Perspective","volume":"16","author":"Williams","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.05.224_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.05.224_bib6","first-page":"737","article-title":"Multidisciplinary teams in clinical lipidology and cardiometabolic care: a National Lipid Association Expert Clinical Review","volume":"19","author":"Cheeley","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.224_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jand.2025.10.010","article-title":"The effectiveness of medical nutrition therapy in prevention and treatment of chronic disease: a position paper of the Academy of Nutrition and Dietetics","volume":"126","author":"Moloney","year":"2026","journal-title":"J Acad Nutr Diet"},{"issue":"1","key":"10.1016\/j.jacl.2026.05.224_bib8","first-page":"8","article-title":"Assessment of the low referral rate of cardiologists to dietitians\/nutritionists","volume":"4","author":"Devries","year":"2021","journal-title":"Int\u00a0J\u00a0Dis\u00a0Rev\u00a0Prev"},{"issue":"1","key":"10.1016\/j.jacl.2026.05.224_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2026.05.224_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12944-025-02658-8","article-title":"Rates of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia in US clinical practice","volume":"24","author":"Sikora Kessler","year":"2025","journal-title":"Lipids Health Dis"},{"issue":"6","key":"10.1016\/j.jacl.2026.05.224_bib11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jacl.2018.09.006","article-title":"The spectrum of type III hyperlipoproteinemia","volume":"12","author":"Sniderman","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"9943","key":"10.1016\/j.jacl.2026.05.224_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacl.2026.05.224_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacl.2026.05.224_bib14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.05.224_bib15","unstructured":"U.S. Food and Drug Administration. Olezarsen package insert [Internet]. U.S. Food and Drug Administration; updated December 2024. Accessed March 13, 2026.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218614s000lbl.pdf."},{"key":"10.1016\/j.jacl.2026.05.224_bib16","unstructured":"U.S. Food and Drug Administration. Plozasiran package insert [Internet]. U.S. Food and Drug Administration;\u00a0updated November 2025. Accessed March 13, 2026.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219947s000lbl.pdf."},{"issue":"19","key":"10.1016\/j.jacl.2026.05.224_bib17","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.224_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacl.2026.05.224_bib19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk","volume":"394","author":"Marston","year":"2026","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.jacl.2026.05.224_bib20","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.224_bib21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.atherosclerosis.2014.09.029","article-title":"Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels","volume":"237","author":"Toth","year":"2014","journal-title":"Atherosclerosis"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426003594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426003594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:36:04Z","timestamp":1790408164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426003594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1933287426003594"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.05.224","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lifestyle and pharmacologic interventions for adults with hypertriglyceridemia: Critical to reduce risk of ASCVD and pancreatitis but often underutilized","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.05.224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}